Note: Descriptions are shown in the official language in which they were submitted.
CA 03010161 2018-06-28
WO 2017/114867 1 PCT/EP2016/082783
CARBOHYDRATE CROSSLINKER
Technical field of the invention
The present invention relates to the field of hydrogels containing crosslinked
polysaccharides and the use of such hydrogels in medical and/or cosmetic
applications. More specifically, the present invention is concerned with
hydrogels made of crosslinked glycosaminoglycans, particularly crosslinked
hyaluronic acid, chondroitin or chondroitin sulfate.
Background of the invention
Water-absorbing gels, or hydrogels, are widely used in the biomedical field.
They are generally prepared by chemical crosslin king of polymers to infinite
networks. While many polysaccharides absorb water until they are completely
dissolved, crosslinked gels of the same polysaccharides can typically absorb
a certain amount of water until they are saturated, i.e. they have a finite
liquid
retention capacity, or swelling degree.
Hyaluronic acid, chondroitin and chondroitin sulfate are well-known
biocompatible polymers. They are naturally occurring polysaccharides
belonging to the group of glycosaminoglycans (GAGs). All GAGs are
negatively charged heteropolysaccharide chains which have a capacity to
absorb large amounts of water.
Hyaluronic acid (HA) is one of the most widely used biocompatible polymers
for medical and cosmetic use. HA is a naturally occurring polysaccharide
belonging to the group of glycosaminoglycans (GAGs). Hyaluronic acid and
products derived from hyaluronic acid are widely used in the biomedical and
cosmetic fields, for instance during viscosurgery and as a dermal filler.
Chondroitin sulfate (CS) is a highly abundant GAG found in the connective
tissues of mammals where it, together with other sulfated GAGs, is bound to
proteins as part proteoglycans. It has previously been shown that hydrogels
containing CS successfully can be used in biomedical applications due to
CA 03010161 2018-06-28
WO 2017/114867 2 PCT/EP2016/082783
their resemblance to the natural extra cellular matrix (Lauder, R.M.,
Complement Ther Med 17: 56-62, 2009). Chondroitin sulfate is also used in
the treatment of osteoarthritis, e.g. as a dietary supplement.
Crosslin king of the glycosaminoglycans prolongs the duration of the
degradable polymers that make up the network, which is useful in may
application. However, the crosslinking can also reduce the native properties
of the glycosaminoglycans. Hence, it is typically desired to maintain a low
degree of modification by efficient crosslinking to conserve the native
properties and effects of the glycosaminoglycan itself.
Summary of the invention
It is an object of the present invention to provide a hydrogel having a
glycosaminoglycan (GAG) as the swellable polymer.
It is a further object of the present invention to provide a method for
crosslinking GAG molecules with reduced effect of the native properties of the
GAG molecules.
It is also an object of the present invention to provide a method for
preparing
hydrogels of GAG molecules by mild and efficient routes.
For these and other objects that will be evident from this disclosure, the
present invention provides according to a first aspect a hydrogel product
comprising glycosaminoglycan molecules as the swellable polymer, wherein
the glycosaminoglycan molecules are covalently crosslinked via crosslinks
comprising a spacer group selected from the group consisting of di-, tri-,
tetra-, and oligosaccharides.
With reference to the inventive processes of preparing hydrogel products
described herein, the term "crosslinker" refers to a molecule having two or
more functional groups, particularly nucleofile functional groups attached to
a
non-reactive spacer group, particularly a di-, tri-, tetra-, or
oligosaccharide.
CA 03010161 2018-06-28
WO 2017/114867 3 PCT/EP2016/082783
Each of the two or more functional groups is capable of reacting with
carboxylic acid groups on the GAG molecules to form stable covalent bonds.
Preferably, the crosslinker consists of the two or more functional groups and
the spacer.
With reference to the inventive hydrogel products described herein, the term
"crosslink" refers to the portion, or residue, of the crosslinker by which the
GAG molecules are covalently linked after crosslinking. The crosslink
typically
consists of i) the spacer group and ii) the binding groups formed upon
reaction of the functional groups of the crosslinker with the carboxylic acid
groups on the GAG. The spacer group may for example be comprised of a
hyaluronic acid tetrasaccharide, hyaluronic acid hexasaccharide, trehalose,
lactose, maltose, sucrose, cellobiose or raffinose residue.
Crosslin king via crosslinkers comprising a spacer group selected from the
group consisting of di-, tri-, tetra-, and oligosaccharides provides a
hydrogel
product based entirely on carbohydrate type structures or derivatives thereof,
which minimizes the disturbance of the crosslinking on the native properties
of the glycosaminoglycans. The di-, tri-, tetra-, or oligosaccharide is
preferably
well defined in terms of structure and molecular weight. Preferably the spacer
is selected from one specific di-, tri-, tetra-, or oligosaccharide structure.
Preferably, the di-, tri-, tetra-, or oligosaccharide is mono-disperse or has
a
narrow molecular weight distribution. Using well defined di-, tri-, tetra-, or
oligosaccharide based crosslinkers together with a highly efficient
condensation reaction allows the product to be assembled in a controlled
fashion. The crosslinker itself can also contribute to maintained or increased
properties of the hydrogel, for example when crosslinking with a structure
that
correlates to hyaluronic acid (e.g. diamino hyaluronic acid tetrasaccharide)
or
when crosslinking with a structure with high water retention properties (e.g.
trehalose).
The GAG may for example be sulfated or non-sulfated glycosaminoglycans
such as hyaluronan, chondroitin sulphate, heparan sulphate, heparosan,
84345475
4
heparin, dermatan sulphate and keratan sulphate. In some embodiments the GAG
is
hyaluronic acid, chondroitin or chondroitin sulfate. In a preferred embodiment
the GAG is
hyaluronic acid.
In preferred embodiments, the GAG is a native GAG. The GAG used in connection
with the
invention is preferably a naturally occurring GAG. The GAG is preferably used
in its native
state. I.e., the chemical structure of the GAG has preferably not been altered
or modified by
addition of functional groups or the like. Using the GAG in its native state
is preferred
because this will afford a crosslinked structure more closely resembling the
natural
molecules, which conserves the native properties and effects of the GAG
itself, and can
minimize the immune response when the crosslinked GAG is introduced into the
body.
The covalently crosslinked GAG molecules preferably consist, or essentially
consist of
carbohydrate type structures or derivatives thereof. This means that the
crosslinked GAG
molecules are preferably free, or essentially free from synthetic non-
carbohydrate structures
or linkers. This can be achieved by using a GAG in its native state together
with a
crosslinker which consist, or essentially consist of carbohydrate type
structures or
derivatives thereof. Functional groups of the crosslinker are then covalently
bound directly
to carboxyl groups of the GAG. The crosslinks of the covalently crosslinked
GAG thus
preferably consist, or essentially consist of di-, tri-, tetra-, and
oligosaccharide spacer
groups.
The present disclosure thus provides a hydrogel product comprising
glycosaminoglycan
molecules as the swellable polymer, wherein the glycosaminoglycan molecules
are
covalently crosslinked via crosslinks comprising a spacer group selected from
the group
consisting of di-, tri-, tetra-, and oligosaccharides, wherein the crosslinked
glycosaminoglycan molecules are free, or essentially free, from synthetic non-
carbohydrate
structures or linkers.
The present invention provides according to a second aspect a process of
preparing a
hydrogel product comprising crosslinked glycosaminoglycan molecules,
comprising the
steps of:
(a) providing a solution of glycosaminoglycan molecules;
(b) activating carboxyl groups on the glycosaminoglycan molecules with a
coupling agent to
form activated, glycosaminoglycan molecules;
Date Recue/Date Received 2023-03-16
CA 03010161 2018-06-28
WO 2017/114867 5 PCT/EP2016/082783
(c) crosslinking the activated glycosaminoglycan molecules via their activated
carboxyl groups using a di- or multinucleophile functional crosslinker
comprising a spacer group selected from the group consisting of di-, tri-,
tetra-, and oligosaccharides to obtain crosslinked glycosaminoglycan
molecules.
The present invention involves crosslinking of glycosaminoglycan molecules
by covalent bonds, preferably amide bonds, typically using an activating
agent for the carboxyl groups on the glycosaminoglycan molecule backbone
and a di- or multinucleophile functional crosslinker comprising a spacer group
selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.
Crosslin king according to the inventive method can be achieved by mild and
efficient routes resulting in high yields with minimal degradation of the GAG
molecules.
The di- or multinucleophile functional crosslinker contains a spacer group
selected from the group consisting of di-, tri-, tetra-, and oligosaccharides,
which remains in the crosslinks between the GAG molecules. The di- or
multinucleophile functional di-, tri-, tetra-, and oligo-saccharides comprise
at
least two nucleophile functional groups attached thereto. The at least two
nucleophile functional groups are preferably separated by the spacer group
selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.
The di- or multinucleophile functional crosslinker comprises two or more
functional groups capable of reacting with functional carboxyl groups of the
GAG, resulting in the formation of covalent bonds, preferably amide bonds.
The nucleophile functional groups are preferably capable of reacting with
carboxyl groups on the glycosaminoglycan molecule to form amide bonds. In
some embodiments the nucleophile functional groups of the di-, tri-, tetra-,
and oligosaccharides are selected from the group consisting of primary
amine, hydrazine, hydrazide, carbazate, semi-carbazide, thiosemicarbazide,
thiocarbazate and aminoxy.
CA 03010161 2018-06-28
WO 2017/114867 6 PCT/EP2016/082783
The di- or multinucleophile functional di-, tri-, tetra-, and oligo-
saccharides
may be derived from nucleophile functional polysaccharides, such as
chitobiose derived from chitin. The di- or multinucleophile functional di-,
tri-,
tetra-, and oligo-saccharides may also be di-, tri-, tetra-, and oligo-
saccharides which have been modified by introduction of two or more
nucleophile functional groups.
A preferred group of di- or multinucleophile functional crosslinker includes
homo- or heterobifunctional primary amines, hydrazines, hydrazides,
carbazates, semi-carbazides, thiosemicarbazides, thiocarbazates and
aminoxy.
In certain embodiments, the activation step (b) and the crosslinking step (c)
occur simultaneously. In other embodiments, the activation step (b) occurs
prior to and separately from the crosslinking step (c).
In a preferred embodiment, step (c) further comprises providing particles of
the crosslinked GAG molecule, having an average size in the range of 0.01-5
mm, preferably 0.1-0.8 mm.
In one preferred embodiment, the coupling agent of step (b) is a peptide
coupling reagent. The peptide coupling reagent may be selected from the
group consisting of triazine-based coupling reagents, carbodiimide coupling
reagents, imidazolium-derived coupling reagents, Oxyma and COMU. A
preferred peptide coupling reagent is a triazine-based coupling reagent,
including the group consisting of 4-(4,6-dimethoxy-1,3,5-triazin-2-yI)-4-
methylmorpholinium chloride (DMTMM) and 2-chloro-4,6-dimethoxy-1,3,5-
triazine (CDMT), preferably DMTMM. Another preferred peptide coupling
reagent is a carbodiimide coupling reagent, preferably N-(3-
dimethylaminopropyI)-N'-ethylcarbodiimide (EDC) combined with N-
hydroxysuccinimide (NHS).
CA 03010161 2018-06-28
WO 2017/114867 7 PCT/EP2016/082783
According to a related aspect, the present invention also provides use of the
hydrogel product as a medicament, such as in the treatment of soft tissue
disorders. There is provided a method of treating a patient suffering from a
soft tissue disorder by administering to the patient a therapeutically
effective
amount of the hydrogel product. There is also provided a method of providing
corrective or aesthetic treatment to a patient by administering to the patient
a
therapeutically effective amount of the hydrogel product.
Other aspects and preferred embodiments of the present invention will be
evident from the following detailed disclosure of the invention and the
appended claims.
Itemized listing of preferred embodiments
1. A hydrogel product comprising glycosaminoglycan molecules as the
swellable polymer, wherein the glycosaminoglycan molecules are covalently
crosslinked via crosslinks comprising a spacer group selected from the group
consisting of di-, tri-, tetra-, and oligosaccharides.
2. A hydrogel product according to embodiment 1, wherein the
glycosaminoglycan molecules are selected from the group consisting of
hyaluronic acid, chondroitin and chondroitin sulfate, and mixtures thereof.
3. A hydrogel product according to embodiment 2, wherein the
glycosaminoglycan molecules are hyaluronic acid.
4. A hydrogel product according to any one of the preceding embodiments,
wherein at least 75 % of the crosslinks comprise a spacer group selected
from the group consisting of di-, tri-, tetra-, and oligosaccharides.
CA 03010161 2018-06-28
WO 2017/114867 8 PCT/EP2016/082783
5. A hydrogel product according to embodiment 4, wherein at least 90 % of
the crosslinks comprise a spacer group selected from the group consisting of
di-, tri-, tetra-, and oligosaccharides.
6. A hydrogel product according to embodiment 5, wherein at least 95 % of
the crosslinks comprise a spacer group selected from the group consisting of
di-, tri-, tetra-, and oligosaccharides.
7. A hydrogel product according to any one of the preceding embodiments,
wherein the spacer group is a hyaluronic acid tetrasaccharide, hyaluronic acid
hexasaccharide, trehalose, lactose, maltose, sucrose, cellobiose or raffinose
residue.
8. A hydrogel product according to embodiment 7, wherein the spacer group
is a hyaluronic acid tetrasaccharide or hyaluronic acid hexasaccharide
residue.
9. A hydrogel product according to embodiment 7, wherein the spacer group
is a trehalose, lactose, maltose, sucrose, cellobiose or raffinose residue.
10. A hydrogel product according to any one of the preceding embodiments,
wherein the spacer group is selected from the group consisting of di-, tri-,
and
tetrasaccharides.
11. A hydrogel product according to any one of the preceding embodiments,
wherein the crosslinks are bound to the glycosaminoglycan molecules by
amide bonds.
12. A hydrogel product according to any one of the preceding embodiments,
wherein at least 75 % of the bonds between glycosaminoglycan molecules
and crosslinks are amide bonds.
CA 03010161 2018-06-28
WO 2017/114867 9 PCT/EP2016/082783
13. A hydrogel product according to embodiment 12, wherein at least 90% of
the bonds between glycosaminoglycan molecules and crosslinks are amide
bonds.
14. A hydrogel product according to embodiment 13, wherein at least 95% of
the bonds between glycosaminoglycan molecules and crosslinks are amide
bonds.
15. A hydrogel product according to any one of the preceding embodiments,
wherein less than 5 % of the bonds between glycosaminoglycan molecules
and crosslinks are ester bonds.
16. A hydrogel product according to embodiment 15, wherein less than 1 % of
the bonds between glycosaminoglycan molecules and crosslinks are ester
bonds.
17. A hydrogel product according to any one of the preceding embodiments,
wherein the crosslinked glycosaminoglycan molecule is in the form of gel
particles having an average size in the range of 0.01-5 mm, preferably 0.1-0.8
mm.
18. A hydrogel product according to any one of the preceding embodiments,
in the form of an injectable formulation.
19. A process of preparing a hydrogel product comprising crosslinked
glycosaminoglycan molecules, comprising the steps of:
(a) providing a solution of glycosaminoglycan molecules;
(b) activating carboxyl groups on the glycosaminoglycan molecules with a
coupling agent to form activated, glycosaminoglycan molecules;
(c) crosslin king the activated glycosaminoglycan molecules via their
activated
carboxyl groups using a di- or multinucleophile functional crosslinker
comprising a spacer group selected from the group consisting of di-, tri-,
CA 03010161 2018-06-28
WO 2017/114867 10 PCT/EP2016/082783
tetra-, and oligosaccharides to obtain crosslinked glycosaminoglycan
molecules.
20. A process according to embodiment 19, wherein the crosslinking of step
(c) provides amide bonds between glycosaminoglycan molecules and
crosslinkers.
21. A process according to any one of embodiments 19-20, wherein the
activation step (b) and the crosslinking step (c) occur simultaneously.
22. A process according to any one of embodiments 19-21, wherein the
coupling agent and the crosslinker are added to the glycosaminoglycan
simultaneously.
23. A process according to any one of embodiments 19-20, wherein the
activation step (b) occurs prior to and separately from the crosslinking step
(c).
24. A process according to any one of embodiments 19-23, wherein step (c)
further comprises providing particles of the crosslinked glycosaminoglycan,
having an average size in the range of 0.01-5 mm, preferably 0.1-0.8 mm.
25. A process according to any one of embodiments 19-24, wherein the
glycosaminoglycan molecules are selected from the group consisting of
hyaluronic acid, chondroitin and chondroitin sulfate, and mixtures thereof.
26. A process according to any one of embodiments 19-25, wherein the
glycosaminoglycan molecules are hyaluronic acid.
27. A process according to any one of embodiments 19-26, wherein the
coupling agent of step (b) is a peptide coupling reagent.
CA 03010161 2018-06-28
WO 2017/114867 11 PCT/EP2016/082783
28. A process according to embodiment 27, wherein the peptide coupling
reagent is selected from the group consisting of triazine-based coupling
reagents, carbodiimide coupling reagents, imidazolium-derived coupling
reagents, Oxyma and COMU.
29. A process according to embodiment 28, wherein the peptide coupling
reagent is a triazine-based coupling reagent.
30. A process according to embodiment 29, wherein the triazine-based
coupling reagent is selected from the group consisting of 4-(4,6-dimethoxy-
1,3,5-triazin-2-y1)-4-methylmorpholinium chloride (DMTMM) and 2-chloro-4,6-
dimethoxy-1,3,5-triazine (CDMT).
31. A process according to embodiment 30, wherein the triazine-based
coupling reagent is DMTMM.
32. A process according to embodiment 28, wherein the peptide coupling
reagent is a carbodiimide coupling reagent.
33. A process according to embodiment 32, wherein the carbodiimide
coupling reagent is N-(3-dimethylaminopropy1)-N'-ethylcarbodiimide ([DC)
combined with N-hydroxysuccinimide (NHS).
34. A process according to any one of embodiments 19-33, wherein the
spacer group is a hyaluronic acid tetrasaccharide, hyaluronic acid
hexasaccharide, trehalose, lactose, maltose, sucrose, cellobiose or raffinose
residue.
35. A process according to any one of embodiments 19-33, wherein the
spacer group is a hyaluronic acid tetrasaccharide or hyaluronic acid
hexasaccharide residue.
CA 03010161 2018-06-28
WO 2017/114867 12 PCT/EP2016/082783
36. A process according to any one of embodiments 19-33, wherein the
spacer group is a trehalose, lactose, maltose, sucrose, cellobiose or
raffinose
residue.
37. A process according to any one of embodiments 19-36, wherein the
spacer group is selected from the group consisting of di-, tri-, and
tetrasaccharides.
38. A process according to any one of embodiments 19-37, wherein the
nucleophilic groups of the crosslinker are selected from the group consisting
of primary amine, hydrazine, hydrazide, carbazate, semi-carbazide,
thiosemicarbazide, thiocarbazate and aminoxy.
39. A process according to embodiment 38, wherein the nucleophilic groups
of the di-, tri-, tetra-, and oligosaccharides are primary amine.
40. A process according to embodiment 39, wherein the crosslinker is a
dinucleofile functional crosslinker.
41. A process according to embodiment 40, wherein the crosslinker is
selected from the group consisting of diamino hyaluronic acid tetrasaccharide,
diamino hyaluronic acid hexasaccharide, diamino trehalose, diamino lactose,
diamino maltose, diamino sucrose, chitobiose, or diamino raffinose.
42. A process according to any one of embodiments 19-41, further comprising
the step:
(d) subjecting the crosslinked glycosaminoglycan molecules obtained in step
(c) to alkaline treatment.
43. Product obtainable by the process according to any one of embodiments
19-42.
CA 03010161 2018-06-28
WO 2017/114867 13 PCT/EP2016/082783
44. A hydrogel product according to any one of embodiments 1-18 and 43 for
use as a medicament.
45. A hydrogel product according to embodiment 44 for use in the treatment
of soft tissue disorders.
46. Use of a hydrogel product according to any one of embodiments 1-18 and
43 for the manufacture of a medicament for treatment of soft tissue disorders.
47. A method of treating a patient suffering from a soft tissue disorder by
administering to the patient a therapeutically effective amount of a hydrogel
product according to any one of embodiments 1-18 and 43.
48. A method of providing corrective or aesthetic treatment to a patient by
administering to the patient a therapeutically effective amount of a hydrogel
product according to any one of embodiments 1-18 and 43.
49. A method of cosmetically treating skin, which comprises administering to
the skin a hydrogel product according to any one of embodiments 1-18 and
43.
Detailed description of the invention
The present invention provides advantageous processes for preparing
hydrogels made of crosslinked glycosaminoglycan (GAG) molecules, the
resulting hydrogel products and uses thereof. GAGs are negatively charged
heteropolysaccharide chains which have a capacity to absorb large amounts
of water. In the hydrogel products according to the invention, the crosslinked
GAG molecule is the swellable polymer which provides the gel properties.
The preparation process described herein is mild to the GAG molecules but
provides an efficient crosslinking.
Thus, the current invention provides GAG molecule hydrogels by crosslinking
in aqueous media using di- or multinucleophile functional crosslinker capable
CA 03010161 2018-06-28
WO 2017/114867 14 PCT/EP2016/082783
of forming covalent bonds directly with carboxylic acid groups of GAG
molecules by a reaction involving the use of a coupling agent.
The GAG according to the invention is preferably selected from the group
consisting of hyaluronic acid, chondroitin and chondroitin sulfate. In a
preferred embodiment, the GAG molecule is hyaluronic acid. Hyaluronic acid
(HA) is one of the most widely used biocompatible polymers for medical and
cosmetic use. HA is a naturally occurring polysaccharide belonging to the
group of glycosaminoglycans (GAGs). Hyaluronic acid and products derived
from hyaluronic acid are widely used in the biomedical and cosmetic fields,
for
instance during viscosurgery and as a dermal filler.
Unless otherwise provided, the term "hyaluronic acid" encompasses all
variants and combinations of variants of hyaluronic acid, hyaluronate or
hyaluronan, of various chain lengths and charge states, as well as with
various chemical modifications. That is, the term also encompasses the
various hyaluronate salts of hyaluronic acid with various counter ions, such
as
sodium hyaluronate. The hyaluronic acid can be obtained from various
sources of animal and non-animal origin. Sources of non-animal origin include
yeast and preferably bacteria. The molecular weight of a single hyaluronic
acid molecule is typically in the range of 0.1-10 MDa, but other molecular
weights are possible.
The term "chondroitin" refers to GAGs having a disaccharide repeating unit
consisting of alternating non-sulfated D-glucuronic acid and N-acetyl-D-
galactosamine moieties. For avoidance of doubt, the term "chondroitin" does
not encompass any form of chondroitin sulfate.
The term "chondroitin sulfate" refers to GAGs having a disaccharide repeating
unit consisting of alternating D-glucuronic acid and N-acetyl-D-galactosamine
moieties. The sulfate moiety can be present in various different positions.
Preferred chondroitin sulfate molecules are chondroitin-4-sulfate and
chondroitin-6-sulfate.
CA 03010161 2018-06-28
WO 2017/114867 15 PCT/EP2016/082783
The chondroitin molecules can be obtained from various sources of animal
and non-animal origin. Sources of non-animal origin include yeast and
preferably bacteria. The molecular weight of a single chondroitin molecule is
typically in the range of 1-500 kDa, but other molecular weights are possible.
The crosslinked GAG comprises crosslinks between the GAG molecule
chains, which creates a continuous network of GAG molecules which is held
together by the covalent crosslinks.
The GAG molecule chains are preferably crosslinked to each other via
crosslinkers comprising a spacer group selected from the group consisting of
di-, tri-, tetra-, and oligosaccharides.
It is preferred that the crosslinkers are bound to the glycosaminoglycan
molecules by amide bonds.
The crosslinked GAG product is preferably biocompatible. This implies that
no, or only very mild, immune response occurs in the treated individual. That
is, no or only very mild undesirable local or systemic effects occur in the
treated individual.
The crosslinked product according to the invention is a gel, or a hydrogel.
That is, it can be regarded as a water-insoluble, but substantially dilute
crosslinked system of GAG molecules when subjected to a liquid, typically an
aqueous liquid.
The gel contains mostly liquid by weight and can e.g. contain 90-99.9%,
water, but it behaves like a solid due to a three-dimensional crosslinked GAG
molecule network within the liquid. Due to its significant liquid content, the
gel
is structurally flexible and similar to natural tissue, which makes it very
useful
as a scaffold in tissue engineering and for tissue augmentation. It is also
CA 03010161 2018-06-28
WO 2017/114867 16 PCT/EP2016/082783
useful for treatment of soft tissue disorder and for corrective or aesthetic
treatment. It is preferably used as an injectable formulation.
Crosslin king of the GAG molecule may be achieved by activation with a
coupling agent, followed by reaction with a crosslinking agent. The GAG
molecule concentration and the extent of crosslinking affect the mechanical
properties, e.g. the elastic modulus G', and stability properties, of the gel.
Crosslinked GAG molecule gels can be characterized in terms of "degree of
modification". The degree of modification of GAG molecule gels generally
range between 0.01 and 15 mole%. The degree of modification (mole%)
describes the amount of crosslinking agent(s) that is bound to the GAG
molecule, i.e. molar amount of bound crosslinking agent(s) relative to the
total
molar amount of repeating disaccharide units. The degree of modification
reflects to what degree the GAG molecule has been chemically modified by
the crosslinking agent. Reaction conditions for activation and crosslinking
and
suitable analytical techniques for determining the degree of modification are
all well known to the person skilled in the art, who easily can adjust these
and
other relevant factors and thereby provide suitable conditions to obtain a
desirable degree of modification and verify the resulting product
characteristics with respect to the degree of modification.
The hydrogel product may also comprise a portion of GAG molecules which
are not crosslinked, i.e not bound to the three-dimensional crosslinked GAG
molecule network. However, it is preferred that at least 50 % by weight,
preferably at least 60 % by weight, more preferably at least 70 % by weight,
and most preferably at least 80 % by weight, of the GAG molecules in a gel
composition form part of the crosslinked GAG molecule network.
The crosslinked GAG molecule is preferably present in the form of gel
particles. The gel particles preferably have an average size in the range of
0.01-5 mm, preferably 0.1-0.8 mm, such as 0.2-0.5 mm or 0.5-0.8 mm.
CA 03010161 2018-06-28
WO 2017/114867 17 PCT/EP2016/082783
The hydrogel product may be present in an aqueous solution, but it may also
be present in dried or precipitated form, e.g. in ethanol. The hydrogel
product
is preferably injectable.
The hydrogel product may be prepared by a process comprising the steps of:
(a) providing a solution of glycosaminoglycan molecules;
(b) activating carboxyl groups on the glycosaminoglycan molecules with a
coupling agent to form activated, glycosaminoglycan molecules;
(c) crosslinking the activated glycosaminoglycan molecules via their activated
carboxyl groups using a di- or multinucleophile functional crosslinker
comprising a spacer group selected from the group consisting of di-, tri-,
tetra-, and oligosaccharides to obtain crosslinked glycosaminoglycan
molecules.
The GAG according to the invention is preferably selected from the group
consisting of hyaluronic acid, chondroitin and chondroitin sulfate. In a
preferred embodiment, the GAG molecule is hyaluronic acid.
In the activation step (b), the carboxyl groups on the GAG molecules are
activated with a coupling agent to form activated GAG molecules.
In one preferred embodiment, the peptide coupling reagent is selected from
the group consisting of triazine-based coupling reagents, carbodiimide
coupling reagents, imidazolium-derived coupling reagents, Oxyma and
COMU.
The peptide coupling reagent is preferably a triazine-based coupling reagent,
such as 4-(4,6-dimethoxy-1,3,5-triazin-2-yI)-4-methylmorpholinium chloride
(DMTMM) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT). A preferred
triazine-based peptide coupling reagent is DMTMM.
CA 03010161 2018-06-28
WO 2017/114867 18 PCT/EP2016/082783
Other preferred peptide coupling reagent are carbodiimide coupling reagents,
preferably N-(3-dimethylaminopropyI)-N'-ethylcarbodiimide (EDC) combined
with N-hydroxysuccinimide (NHS).
In the crosslinking step (c), crosslinking of the activated GAG molecules
occurs via their carboxyl groups using a crosslinker. The crosslinker is a di-
or
multinucleophile functional crosslinker comprising a spacer group selected
from the group consisting of di-, tri-, tetra-, and oligosaccharides. The
crosslinker connects the GAG chains to each other via carboxyl groups on the
GAG backbone. The spacer group may for example be a hyaluronic acid
tetrasaccharide, hyaluronic acid hexasaccharide, trehalose, lactose, maltose,
sucrose, cellobiose or raffinose residue. By the term "residue" is meant here
that the structure of the compound is similar but not identical to the patent
compounds hyaluronic acid tetrasaccharide, hyaluronic acid hexasaccharide,
trehalose, lactose, maltose, sucrose, cellobiose or raffinose respectively.
The
structure of the residue may differ from the structure of the parent compound
in that it has been provided with two or more nucleofile functional groups and
optionally covalently linked via said nucleofile functional groups carboxyl
groups on the GAG backbone.
The di- or multinucleophile functional crosslinker comprises two or more
functional groups capable of reacting with functional carboxyl groups of the
GAG, resulting in the formation of covalent bonds, preferably amide bonds.
A preferred group of di- or multinucleophile functional crosslinker includes
homo- or heterobifunctional primary amines, hydrazines, hydrazides,
carbazates, semi-carbazides, thiosemicarbazides, thiocarbazates and
aminoxy. Non limiting examples of such heterobifunctional crosslinkers useful
in the present invention include:
CA 03010161 2018-06-28
WO 2017/114867 19 PCT/EP2016/082783
NH2
HOH"ol&v,a)
HO
0
1µ04,(14:1F-10.,
OH
OH
0
H2N
Diaminotrehalose (6,6"-diamino-6,6"-dideoxy trehalose);
NH2 OH
H0,0,0\3 0 OH
HO
H
NH2
OH
Diaminosucrose (6,6"-diamino-6,6"-dideoxy sucrose);
OH OH
HO
H. ::1111
NH26\% H0
NH2 OH
Chitobiose (2,2"-diamino-2,2"-dideoxy cellobiose);
HO NH2 NH2
HO
gotiCio 0
HO
OH OH OH
Diaminolactose (6,6"-diamino-6,6"-dideoxy lactose);
_0,L001\Ia OH 4, copi: 1.31 \la OH
0 0 0 0H
HO HO 0 H0
1-1-0,00- 0 HO 0 OH
OH NH2 OH NH2
"Reduced N-Deacetylated hyaluronic acid tetrasaccaride" or
"Reduced diamino hyaluronic acid tetrasaccharide"; and
CA 03010161 2018-06-28
WO 2017/114867 20 PCT/EP2016/082783
NH2
0
HO
HO
= H
= H
voik 0..,?H
H =
HO
= H
0 NH2
OH
Diaminoraffinose (6,6"-diamino-6,6"-dideoxy raffinose).
Reaction schemes la-lh schematically illustrate examples of coupling by
heterobifunctional primary amine (1a), aminoxy (1 b), carbazate (1c), semi-
carbazide (1d), thiosemicarbazide (1e), thiocarbazate (1f), hydrazine (1g) and
hydrazide (1h)
- 0 ONa 0H
0 0
HN HO HO
HO
OH NH 10
0=(
HO 0
HO Na0 0
_ n
- m Amide m
HO
1-10.)
formation
HO
NH2 0
_________________________________ 70
HO OH 0H
HO OH
HO 0
0 = 0 ONa OH . 0 HN
OH 0H
OH HO 0 - Ho HO 0 -
0 OH NH OH NH
H2N 0 0=c
- - -
m n
Scheme 1 a
_ .. .
o o
== 0 ONa 0H - HN HO HN HO
HO 0 0 0 0
OH NH HO
C) HN
\
0 M
_ . In
H2N
µ0 HOH \ Hn'"&õ(6).)
-HO
HO
0
/ ________________________________ OH OH 0H
OH
HO
0
'3%1\1H - 0 ONa OH OH
OH 0
0 HO 0 =-, Ho 0 0
= NH2 OH NH OH
NH
C) 0
.. .- In.
n
Scheme lb
CA 03010161 2018-06-28
WO 2017/114867 21 PCT/EP2016/082783
.. ..
..
)() )=0
HN HO HN HO
OH 0 0
OH
= 0 ONa OH
HN M
HO o 0 NH
OH NH
0=C/
O\
0
.. ..
in
ss
NH
/
__________________________________ Or
\
> 0
H2N
HO
0=C
o1-1
o
\c
HO)
Hefrot
0 I
HN
1µ.Øõ NH
OH 0
0
0 HO HO
\ --0 HO
C--- OH NH OH NH
I 0 0
HNN,
NH2 - = -
m n
Scheme 1c
. _ ..
HN HO HNO HO
0 OH 0 o OH
OH OH __
0 0 0 0
- 0 ONa Na0
0 0 HN 111
HO N
HO 0 01 NH
OH NH /
(r) 0=C
\
NH
-
Mt
H2N \NH H H.. 111H)
/ 0
0=C
\
> k:).11Ø.H
0
NH
H?i(".::&..e.) HN
µ --
HO C--0
0 I
1
HN
OH
,...NH µ..1....
OH = 0 ONa
OH OH
0
HN 0 0
OH NH OH NH
I C) 0
HN,NH2 -
m n
Scheme 1d
CA 03010161 2018-06-28
WO 2017/114867 22 PCT/EP2016/082783
- - -
)=0 )=0
0 HN 0 HO HN 0 HO
OH 0
OH
0 0
- 0 Na OH
HN
0 111
HO l
HO 0 Ot NH
OH NH /
0 S =C
\
NH
-
III
NH
/
= _________________ Va.
\
> HOH HO
S C 0
H2Nõ
IcØ40c;OH Hoil
NH
HOH.:::&.1) HN
0 I
HN
1µ...C;1-0. ....NH
OH
_______40.4...=
Na OH OH
-
0
HN
Ho'....01:34, = 0
= - - S HO 0 0 Ho
0 0
C -''' OH NH OH NH
I HN 0=c 0=(
, NH, - - -
-
m n
Scheme le
_ .. _ -
0 )=0
HN HO HN HO
OH OH
0 0 0 0
- 0 ONa OH - HO HO Na0
HN In
HO'Ø1. ...V.0
HO NH
OH NH /
C) 0 = C
\
S
..
In
I-12N
\ FIC)F1*- **Nil:
NH
/ 0
0=C _____________ 31101
\
> k.Ø4.0,,cm HoH
s
0 I
HN 'NH
OF1µ...
OH
OH ,. o ONa OH OH
0 0 0
S
" ... 0 HO 0 sa H0 0 0
C --- OH NH OH NH
I 0= HN 0,,
NH, .. .. .
m n
Scheme If
CA 03010161 2018-06-28
WO 2017/114867 23 PCT/EP2016/082783
- -
F=O o
- 0 ONa 0H
HN HO HN HO
.I
C)..14104. ,0H 0 H C''...Vc H
OH NH HO 0 _ HO Na0
o HN
N,
NH in
- H M
N
2
NH 0
HO
HO
HO > _____ )1110, HOH0
*HOH
O HN.
OH oFi
HO HO -
OH
0
HO 00
HN 0
HO 0 HO 0 0
= OH NH OH
NH
NH2 (3 0=c
- -
.. n
in.
Scheme 1g .
0 o
HN 0 HO oH HN 0 HO
OH
,,,.=.41:2:1,. ,' e OH . V0411,0H 0
HO 0 0 0 0
OH NH HO 0 _ HO
Na0 9 _ n
O HN,NH m
. \
H2N¨NH HO
C=0
> V,01Ø) _______________________ IND' 0
H'(;:1&01110)
0
F
OH oFi
HO
-HO
HO OH
O 0
OH OH
0 -- =,
OH NH
0 /
HN
...- NH2 110
OH 0
OH NH OH
NH
0
0=c
_ - ,-
m
n
Scheme 1h
The di- or multinucleophile functional crosslinker contains a spacer group
selected from the group consisting of di-, tri-, tetra-, and oligosaccharides,
which remains in the crosslinks between the GAG molecules.
The process may be performed in a one-pot approach in aqueous media,
involving the covalent coupling of di- or multinucleophile functional
crosslinkers directly to inherent carboxylic acid groups on the native GAGs
using a suitable coupling agent. In a preferred embodiment, the activation
step (b) and the crosslinking step (c) occur simultaneously.
CA 03010161 2018-06-28
WO 2017/114867 24 PCT/EP2016/082783
In another embodiment, the activation step (b) occurs prior to and separately
from the crosslinking step (c).
The process for generating the crosslinked hydrogel typically involves
preparing a mixture of a GAG molecule, such as hyaluronic acid together with
a crosslinker agent, such as diamino trehalose, DATH, (0.001 ¨ 10 molar
equivalents of amine towards carboxylic acid groups, or preferably 0.001 ¨ 1
molar equivalents) and a coupling agent such as DMTMM (0.01 ¨ 10 molar
equivalents to carboxylic acid groups, or preferably 0.05 ¨ 1 molar
equivalents). Incubating the mixture at 5 ¨ 50 C, preferably 10 ¨ 40 C or
even more preferred 20 ¨ 35 C, during 2 ¨ 120 hours, preferably 4 ¨48
hours, followed by alkaline treatment, neutralization, precipitation, washing
and dried under vacuum, yields a crosslinked polysaccharide as a solid. The
precipitate was swelled in phosphate buffer containing NaCI to form a
hydrogel, the hydrogel is preferably micronized to hydrogel particles in the
size of 0.01 ¨ 5 mm, preferably 0.1 ¨ 1 mm.
A typical application of the resulting hydrogel product involves the
preparation
of injectable formulations for treatment of soft tissue disorders, including,
but
not limited to, corrective and aesthetic treatments.
In one more specific embodiment, crosslin king of chondroitin sulfate with
DATH may be achieved as follows:
Diaminotrehalose (DATH) is synthesized as described in "Synthetic
Carbohydrate Polymers Containing Trehalose Residues in the Main Chain:
Preparation and Characteristic Properties"; Keisuke Kurita,* Naoko Masuda,
Sadafumi Aibe, Kaori Murakami, Shigeru Ishii, and Shin-lchiro Nishimurat;
Macromolecules 1994, 27, 7544-7549.
Chondroitin Sulfate (CS) (10 - 200 kDa) is weighed in a Falcon tube. A stock
solution of diaminotrehalose (DATH) is prepared by dissolving DATH in
CA 03010161 2018-06-28
WO 2017/114867 25 PCT/EP2016/082783
phosphate buffer pH 7.4. DMTMM is weighed in a vessel and the DATH-
solution is added to the DMTMM. The pH of the DMTMM-DATH solution is
adjusted to approx. 7 by addition of 1.2 M HCl or 0.25 M NaOH, and the
mixture is subsequently added to CS. The contents are thoroughly
homogenized and then incubated at 15-55 C for 2-48 h. The resulting
material is pressed through a 1 mm steel mesh two times and swelled in
NaOH. The gel is neutralized with 1.2 M HCI to pH 7 and precipitated with
ethanol. The resulting precipitate is washed with 100 mM NaCI in 70%
ethanol, with 70% ethanol and ethanol. The obtained solid is dried at 25 C
under vacuum. The precipitate is swelled in 0.7 % NaCI phosphate buffer pH
7.4 and pressed through a filter mesh three times. The crosslinked CS-gel is
filled on syringes and sterilized.
In another more specific embodiment, crosslinking of HA with diaminosucrose
may be achieved as follows:
Diaminosucrose is prepared as described in "Library of mild and economic
protocols for the selective derivatization of sucrose under microwave
irradiation"; M. Teresa Barros, Krasimira T. Petrova, Paula Correia-da-Silva
and Taterao M. Potewar; Green Chem., 2011, 13, 1897-1906.
Hyaluronic acid (HA) (10¨ 1 000 kDa) is weighed in a vessel. A stock solution
of diaminosucrose is prepared by dissolving diaminosucrose in phosphate
buffer pH 7.4. DMTMM is weighed in a vessel and the diaminosucrose-
solution is added to the DMTMM. The pH of the DMTMM-diaminosucrose
solution is adjusted to approx. 7 by addition of 1.2 M HCI or 0.25 M NaOH,
and the mixture is subsequent added to HA. The contents are thoroughly
homogenized and then incubated at 15-55 C for 2-48 h. The resulting
material is pressed through a 1 mm steel mesh two times and swelled in
NaOH. The gel is neutralized with 1.2 M HCI to pH 7 and precipitated with
ethanol. The resulting precipitate is washed with 100 mM NaCI in 70%
ethanol, with 70% ethanol and ethanol. The obtained solid is dried at 25 C
CA 03010161 2018-06-28
WO 2017/114867 26 PCT/EP2016/082783
under vacuum. The precipitate is swelled in 0.7 % NaCI phosphate buffer pH
7.4 and pressed through a filter mesh three times. The crosslinked HA-gel is
filled on syringes and sterilized.
In another more specific embodiment, crosslinking of HA with chitobiose may
be achieved as follows:
Hyaluronic acid (HA) (10¨ 1 000 kDa) is weighed in a vessel. A stock solution
of chitiobiose (purchased from Carbosynth Ltd. UK) is prepared by dissolving
chitobiose in phosphate buffer pH 7.4. DMTMM is weighed in a vessel and
the chitobiose-solution is added to the DMTMM. The pH of the DMTMM-
chitobiose solution is adjusted to approx. 7 by addition of 1.2 M HCI or 0.25
M
NaOH, and the mixture is subsequent added to HA. The contents are
thoroughly homogenized and then incubated at 15-55 C for 2-48 h. The
resulting material is pressed through a 1 mm steel mesh two times and
swelled in NaOH. The gel is neutralized with 1.2 M HCI to pH 7 and then
precipitated with ethanol. The resulting precipitate is washed with 100 mM
NaCI in 70% ethanol, with 70% ethanol and ethanol. The obtained solid is
dried at 25 C under vacuum. The precipitate is swelled in 0.7 % NaCI
phosphate buffer pH 7.4 and pressed through a filter mesh three times. The
crosslinked HA-gel is filled on syringes and sterilized.
In another more specific embodiment, crosslinking of HA with a reduced
diamino HA-tetrasaccharide may be achieved as follows:
Hyaluronic acid (HA) (10¨ 1 000 kDa) is weighed in a vessel. A stock solution
of a reduced diamino HA-tetrasaccharide is prepared by dissolving reduced
diamino HA-tetrasaccharide in phosphate buffer pH 7.4. DMTMM is weighed
in a vessel and the reduced diamino HA-tetrasaccharide solution is added to
the DMTMM. The pH of the DMTMM and reduced diamino HA-
tetrasaccharide solution is adjusted to approx. 7 by addition of 1.2 M HCI or
0.25 M NaOH, and the mixture is subsequent added to HA. The contents are
thoroughly homogenized and incubated at 15-55 C for 2-48 h. The resulting
CA 03010161 2018-06-28
WO 2017/114867 27 PCT/EP2016/082783
material is pressed through a 1 mm steel mesh two times and swelled in
NaOH. The gel is neutralized with 1.2 M HCl to pH 7 and precipitated with
ethanol. The resulting precipitate is washed with 100 mM NaCI in 70%
ethanol, with 70% ethanol and ethanol. The obtained solid is dried at 25 C
under vacuum. The precipitate is swelled in 0.7% NaCI phosphate buffer pH
7.4 and pressed through a filter mesh three times. The crosslinked HA-gel is
filled on syringes and sterilized.
In another more specific embodiment, crosslinking of HA with dicarbazate
trehalose may be achieved as follows:
a,a-D-Trehalose (1 equiv.) (anhydrous) (Carbosynth Ltd. UK) is dissolved in
dry dimethylformamid (DMF), and triethylamine (2-6 equiv.) is added
subsequently. The flask is cooled to 0 C (ice/water) and under N2-
atmosphere. 4-Nitrophenyl chloroformate (2-6 equiv.) is added into the flask
dropwise. The resulting mixture is allowed to stir at room temperature for 2-
48
h and then concentrated, purified by FC and dried under vacuum. The
product is dissolved in DMF, and hydrazine monohydrate (2-20 equiv.) is
added to the solution and stirred at 0 - 50 C for 4 - 48 h. The reaction is
then
concentrated, purified by FC and dried under vacuum to obtain a,a-D-6,6'-
dideoxy-6,6'-dicarbazate trehalose (dicarbazate trehalose, DOT).
Hyaluronic acid (HA) (10¨ 1 000 kDa) is weighed in a vessel. A stock solution
of dicarbazate trehalose (DOT) is prepared by dissolving DOT in phosphate
buffer pH 7.4. DMTMM is weighed in a vessel and the DOT-solution is added
to the DMTMM. The pH of the DMTMM-DOT solution is adjusted to approx. 7
by addition of 1.2 M HCI or 0.25 M NaOH, and the mixture is subsequent
added to HA. The contents are thoroughly homogenized and incubated at 15-
55 C for 2-48 h. The resulting material is pressed through a 1 mm steel mesh
two times and swelled in NaOH. The gel is neutralized with 1.2 M HCI to pH 7
and precipitated with ethanol. The resulting precipitate is washed with 100
mM NaCI in 70% ethanol, with 70% ethanol and ethanol. The obtained solid is
CA 03010161 2018-06-28
WO 2017/114867 28 PCT/EP2016/082783
dried at 25 C under vacuum. The precipitate is swelled in 0.7 % NaCI
phosphate buffer pH 7.4 and then pressed through a filter mesh three times.
The crosslinked HA-gel is filled on syringes and sterilized.
In another more specific embodiment, crosslin king of HA with
diaminoxytrehalose may be achieved as follows:
To a stirred suspension of a,a-D-Trehalose (1 equiv.) (anhydrous)
(Carbosynth Ltd. UK) in anhydrous THF, N-hydroxyphthalimide (2-10 equiv.)
and triphenylphosphine (2-10 equiv.) is added, and the mixture is stirred for
5-
60 min. Diisopropyl azodicarboxylate (DIAD, 2-10 equiv.) is then added
dropwise at 0 - 40 C and the mixture is stirred for 2-48 h at 0 - 40 C. The
solvent is removed in vacuo and the crude product is purified by FC and dried
under vacuum. A suspension of the product in a mixture of Me0H and CH2Cl2
is treated with hydrazine monohydrate (2-20 qeuiv.), and the mixture is
stirred
at 0 - 40 C for 2-24 h followed by concentration, purification by FC and
drying
under vacuum to obtain the diaminoxytrehalose.
Hyaluronic acid (HA) (10¨ 1 000 kDa) is weighed in a vessel. A stock solution
of diaminoxytrehalose (DAOT) is prepared by dissolving DAOT in phosphate
buffer pH 7.4. DMTMM is weighed in a vessel and the DAOT-solution is
added to the DMTMM. The pH of the DMTMM-DAOT solution is adjusted to
approx. 7 by addition of 1.2 M HCl or 0.25 M NaOH, and the mixture is
subsequent added to HA. The contents are thoroughly homogenized and
incubated at 15-55 C for 2-48 h. The resulting material is pressed through a
1 mm steel mesh two times and swelled in NaOH. The gel is neutralized with
1.2 M HCI to pH 7 and precipitated with ethanol. The resulting precipitate is
washed with 100 mM NaCI in 70% ethanol, with 70% ethanol and ethanol.
The obtained solid is dried at 25 C under vacuum. The precipitate is swelled
in 0.7% NaCI phosphate buffer pH 7.4 and then pressed through a filter mesh
three times. The crosslinked HA-gel is filled on syringes and sterilized.
CA 03010161 2018-06-28
WO 2017/114867 29 PCT/EP2016/082783
EXAMPLES
Without desiring to be limited thereto, the present invention will in the
following be illustrated by way of examples.
Definitions and Analysis
SwF ¨ Swelling factor analysis was done in saline.
[PS] ¨ Polysaccharide concentration, e.g. HA concentration. The PS
concentration was measured with LC-SEC-UV or N IR.
GelP ¨ Gel part (also sometimes referred to as gel content or GeIC) is a
description of the percentage of polysaccharide that is a part of the gel
network. A number of 90% means that only 10% of polysaccharide is not a
part of the network. The amount of free polysaccharide in the gel was
measured with LC-SEC-UV.
SwC ¨ swelling capacity is the total liquid uptake of one gram polysaccharide,
not corrected for gel part.
SwF
SwC = ______________________________________
[PS]
SwCC ¨ Corrected swelling capacity (also sometimes referred to as SwDC) is
the total liquid uptake of one gram polysaccharide, corrected for gel part.
SwF
SwCC = ________________________________________
GelP * [PS]
CrR - Effective crosslinking ratio was analyzed with LC-SEC-MS and defined
as:
mol crosslinked crosslinker with amide bonds
CrR =
mot linked crosslinker with amide bonds
A CrR of 1.0 means that all of the crosslinker has crosslinked.
CA 03010161 2018-06-28
WO 2017/114867 30 PCT/EP2016/082783
Alkaline or heat hydrolysis
In some of the examples below, the product was subjected to alkaline or heat
hydrolysis in order to hydrolyze ester bonds formed during the crosslin king
process. The alkaline/heat hydrolysis results in only amide crosslink bonds in
the end product. The alkaline/heat hydrolysis was performed as follows:
Alkaline hydrolysis
The material was swelled in 0.25 M NaOH (1 g material : 9 g 0.25 M NaOH
resulting in pH 13) for at least 1 h at room temperature. The gel was
neutralized with 1.2 M HCI to pH 7 and then precipitated with ethanol. The
resulting precipitate was washed with 100 mM NaCI in 70% ethanol to
remove excess reagents and then with 70% ethanol to remove salts and
finally with ethanol to remove water. Ethanol was removed in a vacuum dryer
overnight.
The precipitate was swelled in 0.7% NaCI phosphate buffer pH 7.4 and then
pressed through a fine filter mesh three times. The gel was filled on syringes
and sterilized. In some cases a couple of the syringes were not sterilized to
see the effect of sterilization.
Heat hydrolysis
The material was swelled in 0.7% NaCI phosphate buffer pH 7.4 at room
temperature. The pH was adjusted to 7.2-7.5 if needed. The gel was left at 70
C for 20-24 h and then particle-size reduced through a fine filter mesh three
times. The gel was filled on syringes and sterilized. In some cases a couple
of
the syringes were not sterilized to see the effect of sterilization.
Synthesis of hyaluronic diaminotrehalose
Diaminotrehalose (DATH) was synthesized as described in "Synthetic
Carbohydrate Polymers Containing Trehalose Residues in the Main Chain:
CA 03010161 2018-06-28
WO 2017/114867 31 PCT/EP2016/082783
Preparation and Characteristic Properties"; Keisuke Kurita,* Naoko Masuda,
Sadafumi Aibe, Kaori Murakami, Shigeru Ishii, and Shin-lchiro Nishimurat;
Macromolecules 1994, 27, 7544-7549.
Example 1 ¨ Crosslinking of Hyaluronic Acid with diaminotrehalose (DATH)
A series of experiments (Examples 1-1 to 1-5) were performed which involved
crosslinking of hyaluronic acid (HA) of different molecular weights with
various
molar ratios of DATH using 4-(4,6-dimethoxy-1,3,5-triazin-2-yI)-4-
methylmorpholinium chloride (DMTMM) as a coupling agent. Ratios between
HA, DATH and DMTMM are set out in Table 1 below.
The hyaluronan (molecular weight (Mw) from about 100 kDa to about 1 000
kDa) was weighed in a Falcon tube. A stock solution of diaminotrehalose
(DATH) was prepared by dissolving DATH (0.001 ¨ 0.005 equiv.) in
phosphate buffer pH 7.4. DMTMM (0.05 equiv.) was weighed in a PTFE-
container and the DATH-solution was added to DMTMM to dissolve it. The pH
of the DMTMM-DATH solution was adjusted to 6-7 with 1.2 M HCI or 0.25 M
NaOH and then added to the HA. The contents were thoroughly homogenized
and then incubated at 35 C for 24 h.
The resulting material was pressed through a 1 mm steel mesh two times and
then treated with a NaOH solution. The gel was neutralized with 1.2 M HCI to
pH 7 and then precipitated with ethanol. The resulting precipitate was washed
with 100 mM NaCI in 70% ethanol to remove excess reagents and then with
70% ethanol to remove salts and finally with ethanol to remove water. Ethanol
was removed in a vacuum dryer over night.
The precipitate was swelled in 0.7% NaCI phosphate buffer pH 7.4 and then
pressed through a filter mesh three times. The gel was filled on syringes and
sterilized.
CA 03010161 2018-06-28
WO 2017/114867 32 PCT/EP2016/082783
Table 1.
Example <Mw> Eq Eq
Monophasic CrR GeIC SwCC
(MDa) DMTMM DATH at (%) (ml/g)
[HA] 50
mg/mL
1-1 1.06 0.05 0.003 No 0.99 NA NA
1-2 1.06 0.05 0.001 Yes 0.99 74 101
1-3 0.64 0.05 0.005 Yes NA 93 38
1-4 0.31 0.05 0.005 Yes NA 85 49
1-5 0.11 0.05 0.005 Yes NA 84 123
NA ¨ not available since the analysis was not done
Example 2 ¨ Crosslinking of Hyaluronic Acid with diaminotrehalose (DATH)
A series of experiments (Examples 2-1 to 2-11) were performed which
involved crosslin king of hyaluronic acid (HA) of different molecular weights
with various molar ratios of DATH using 4-(4,6-dimethoxy-1,3,5-triazin-2-yI)-4-
methylmorpholinium chloride (DMTMM) as a coupling agent. Ratios between
HA, DATH and DMTMM are set out in Table 2 below.
Hyaluronic acid was weighed in a reaction vessel. A stock solution of the
crosslinker (DATH) was prepared by dissolving it in phosphate buffer pH 7.4.
DMTMM was weighed in a PTFE-container and the crosslinker-solution was
added to the DMTMM to dissolve it. The pH of the DMTMM-crosslinker
solution was adjusted to 6-7 with 1.2 M HCI or 0.25 M NaOH and then added
to the HA. The contents were thoroughly homogenized and then incubated at
35 C for 24 h. The resulting material was pressed through a 1 mm steel
mesh two times and then treated with either heat or alkaline. The results are
displayed in Table 2.
Table 2. Summary crosslinking Hyaluronic Acid with (DATH)
Example <Mw> DMTMM/HA DATH/HA DMTMM/ Hydro-
CrR GelP after SwCC 0
tse
=
(MDa) (mol%) (mol%) DATH lysis
sterilization (mug) .
-1
,
,-,
oe
c,
-,1
2-1 1 5.0 0.08 61 Alkaline
0.99 74 101
2-2 1 0.7 0.06 12 Heat
0.51 45 309
2-3 1 2.4 0.03 74 Heat
0.94 55 259
2-4 (n = 4) 0.6 1.2 0.32 3.6 Heat
0.45 72 4 132 23
0
2-5 (n = 4) 0.6 1.2 0.32 3.6 Alkaline
0.43 63 1 218+13 0
2-6 0.3 5.0 0.25 20 Alkaline
77 79
rs,
2-7 0.2 4.9 0.57 8.7 Heat
0.86 77 106
i
0
,
_
rs,
2-8 0.2 4.0 0.57 7.0 Alkaline
0.63 52 445
2-9 0.1 4.5 0.65 7.0 Heat
0.55 50 337
2-10 0.1 6.9 0.79 8.8 Heat
0.89 91 91
2-11 0.1 5.5 0.65 8.5 Heat
0.75 87 146
n
Empty cells - no analysis done.
c,
,
=
oc
ka
-,1
x
ta
CA 03010161 2018-06-28
WO 2017/114867 34 PCT/EP2016/082783
Example 3 ¨ Crosslin king of Hyaluronic Acid with Chitobiose (CB)
Hyaluronic acid was weighed in a reaction vessel. A stock solution of the
crosslinker (chitobiose) was prepared by dissolving it in phosphate buffer pH
7.4. DMTMM was weighed in a PTFE-container and the crosslinker-solution
was added to the DMTMM to dissolve it. The pH of the DMTMM-crosslinker
solution was adjusted to 6-7 with 1.2 M HCI and then added to the HA. The
contents were thoroughly homogenized and then incubated at 35 C for 24 h.
The resulting material was pressed through a 1 mm steel mesh two times and
then treated with either heat or alkaline according to the general procedures.
Ratios between HA, chitobiose and DMTMM are set out below in Table 3
(Examples 3-1 to 3-2).
Example 4 - Crosslinking of Hyaluronic Acid with diaminotetra-HA (DA-4HA)
Diaminotetra-HA (DA-4HA) was synthesized according to below scheme:
OH 0 OH 0
HO HO o HO
HO 0 Ho 0
OH ,NH OH NH OH
\
/
(....)NaOHOH 0H
HO HO 0 HO OH
HO 0 Ho 0
OH (:),NH OH NH
1 N
/
OH 0 OH 0H
HO HO o HO OH
HO 0 Ho 0
OH NH2 OH 8H2
2
+
c....2:64,.... 0 ONa
OH 0 OH
HO HO o HO 0H OH
HO 0 Ho 0
OH 0 NH OH NH2
--µ 3
CA 03010161 2018-06-28
WO 2017/114867 35 PCT/EP2016/082783
Step 1
A solution of HA-4 (500 mg, 0.61 mmol) in water (5 ml) at room temperature
was treated with sodium borohyride (23.05 mg, 0.61 mmol) and the resulting
solution was stirred for 3 h, concentrated to dryness to afford the reduced
product 1 (532 mg, assumed 100%) as a white foam.
LCMS (tr = 0.28 min., ES+ = 779.4 (M-2 Na + 2H)
Step 2
The reduced product 1 (532 mg) was dissolved in aqueous NH2OH (5 ml,
50% v/v/) and solid NH41(100 mg) was added. The resulting suspension was
heated at 70 C for 48 h, cooled to room temperature and concentrated to
dryness to afford a residue. The residue was precipitated in neat Et0H and
the resulting precipitate was collected by filtration and dried to a constant
weight to afford the a 1:1 mixture of diamine 2 and mono-amine 3 in
quantitative yield. The crude reaction product was used without further
purification.
2 : LCMS (tr = 0.16 min., ES+ = 695.36 (M-2 Na + 2H)
3: LCMS (tr = 0.19 min., ES+ = 737.47 (M-2 Na + 2H)
Hyaluronic acid was weighed in a reaction vessel. A stock solution of the
crosslinker (diaminotetra-HA), synthesized as described above, and DMTMM
respectively were prepared by dissolving it in phosphate buffer pH 7.4. The
pH of the solutions were adjusted to 7 and then added to the HA. The
contents were thoroughly homogenized and then incubated at 23 C for 24 h.
The resulting material was pressed through a 1 mm steel mesh two times and
then treated with heat according to the general procedures. Ratio between
HA, diaminotetra-HA and DMTMM are set out below in Table 3 (Example 4).
Example 5 - Crosslinking of Heparosan (HEP) with diaminotrehalose (DATH)
The coupling agent DMTMM and the crosslinker DATH were weighed in
separate reaction vessels and dissolved in phosphate buffer (pH 7.4). The
CA 03010161 2018-06-28
WO 2017/114867 36 PCT/EP2016/082783
solutions pH was adjusted to pH 7-7.5 with 1.2 M HCI or 0.25 M NaOH.
Thereafter, DMTMM- and DATH-solutions were successively added to the
heparosan weighed in a reaction vessel. The contents were thoroughly
homogenized and then incubated at 35 C for 24 h. The resulting material
was pressed through a 1 mm steel mesh two times and then treated with heat
according to the general procedures. Ratios between heparosan, DATH and
DMTMM are set out in Table 3 below (Examples 5-1 to 5-2).
Example 6 ¨ Crosslinking of Chondroitin Sulfate (CS) with diaminotrehalose
(DATH)
The coupling agent DMTMM and the crosslinker DATH were weighed in
separate reaction vessels and dissolved in phosphate buffer (pH 7.4). The
solutions pH was adjusted to pH 7-7.5 with 1.2 M HCI or 0.25 M NaOH.
Thereafter, DMTMM- and DATH-solutions were successively added to the
chondroitin sulfate weighed in a reaction vessel. The contents were
thoroughly homogenized and then incubated at 35 C for 24 h. The resulting
material was pressed through a 1 mm steel mesh two times and then treated
with heat according to the general procedures. Ratios between chondroitin
sulfate, DATH and DMTMM are set out below in Table 3 (Examples 6-1 to 6-
2).
0
t.4
Table 3. Summary crosslinking examples 3-6
-1
,
,-,
4..
PS Cross- DMTMM/PS Crosslinker/ DMTMW Hydro-
GelP SwCC SwC G' 0.1 Hz g
Example
-)
Mw linker (mol%) PS
(mol%) crosslinker lysis (%) (mL/g) (mL/g) (kPa)
HA
3-1 1 MDa CB 2.4 0.13 18.5 Heat
60 224
HA
3-2 1 MDa CB 2.4 0.13 18.5 Alkaline
45 335
HA DA-
4 24 1.0 24 Heat
47 P
0.2 MDa 4HA
.
.
.
140
5-1 DATH 7 1.0 7 Heat
36 175
HEPkDa
õ
.
HEP
.
5-2 DATH 10.5 1.5 7 Heat
80 101 .
140 kDa
g,
03
CS
6-1 30 kDA DATH 35 5.0 7.0
Heat 48 1.6
6-2 CSDATH 35 5.0 7.0 Heat
44 1.5
30 kDa
ti
n
i-i
PS = polysaccharide, HA = hyaluronan, HEP = heparosan, CS = chondroitin
sulfate, DA-4HA = diaminotetra-HA, CB =
ti
chitobiose
w
=
c,
,
=
Empty cells ¨ no analysis done.
oe
t.,
,1
oe
t,4
